Literature DB >> 14535868

Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication.

J P Gisbert1, S Khorrami, X Calvet, R Gabriel, F Carballo, J M Pajares.   

Abstract

BACKGROUND: It is unknown whether proton pump inhibitors are superior to H2-receptor antagonists in Helicobacter pylori eradication regimens. AIM: To perform a meta-analysis comparing the efficacy of both antisecretors when co-prescribed with antibiotics.
METHODS: Randomized clinical trials comparing proton pump inhibitors vs. H2-receptor antagonists with the same antibiotics were selected. Data sources included PubMed, the Cochrane Controlled Trials Register and abstracts from congresses up to January 2002. A meta-analysis was performed by combining the odds ratios.
RESULTS: Twenty studies fulfilled the inclusion criteria. In the intention-to-treat analysis, the mean eradication rates with proton pump inhibitors and H2-receptor antagonists plus antibiotics were 74% [95% confidence interval (CI), 71-76%] and 69% (95% CI, 66-71%), respectively. The odds ratio for this comparison was 1.31 (95% CI, 1.09-1.58). The number needed to treat with proton pump inhibitors to achieve eradication success, compared with H2-receptor antagonists, was 25. When studies prescribing very high doses of H2-receptor antagonists (two of the outliers) were excluded, the odds ratio (for proton pump inhibitors vs. H2-receptor antagonists) increased to 1.37, the number needed to treat decreased to 20 and the heterogeneity between the studies decreased.
CONCLUSIONS: Overall, proton pump inhibitors are more effective than H2-receptor antagonists when prescribed at usual doses with antibiotics to eradicate H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14535868     DOI: 10.1046/j.1365-2036.2003.01766.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  17 in total

1.  Influence of antisecretory drugs on Helicobacter pylori eradication rates.

Authors:  M Pellegrini; R Urso; G Giorgi; D Cerretani; R C Spiller; P Sherwood
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

Review 2.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Proton pump inhibitors: use, misuse and concerns about long-term therapy.

Authors:  T P Rakesh
Journal:  Clin J Gastroenterol       Date:  2011-02-18

4.  Hypersensitivity reaction to omeprazole in a patient treated for Helicobacter pylori.

Authors:  Sarah Anderson; Sarah Christensen
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 5.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Optimising acid inhibition treatment.

Authors:  Fernando Gomollón; Xavier Calvet
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

8.  Liver hepatotoxicity associated with pantoprazole: a rare case report.

Authors:  Mehmet Aslan; Yilmaz Celik; Sevdegul Karadas; Sehmus Olmez; Adem Cifci
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

9.  Inhibition of lysosomal enzyme activities by proton pump inhibitors.

Authors:  Wensheng Liu; Susan S Baker; Jonathan Trinidad; Alma L Burlingame; Robert D Baker; John G Forte; Lauren P Virtuoso; Nejat K Egilmez; Lixin Zhu
Journal:  J Gastroenterol       Date:  2013-03-12       Impact factor: 7.527

10.  Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.

Authors:  Giuliana Sereni; Francesco Azzolini; Lorenzo Camellini; Debora Formisano; Francesco Decembrino; Veronica Iori; Cristiana Tioli; Maurizio Cavina; Francesco Di Mario; Giuliano Bedogni; Romano Sassatelli
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.